Hi, Just got back from the States and last week the New York...

Hi,
Just got back from the States and last week the New York Post had a full page devoted to the competition between Opitivo and Keytruda.The Dollar values were staggering for market share.
The general subject was to do with Optivo failing the Lung cancer trials giving Merck the edge but also it was mentioned it was now all about combinations.
Combinations which is what Mccoll is trying to prove.
I think we are on the cusp of some serious share price movement if we can generate strong trial results.
Only weeks away from knowing.

Aloha.